Stay updated with breaking news from Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roivant Sciences Ltd is attracting interest from large pharmaceutical companies for its inflammatory bowel disease drug, Bloomberg News reported on Thursday, citing people familiar with the matter. ...
SPC Life Sciences has received approval from the Securities and Exchange Board of India (Sebi) to raise funds through an initial public offering (IPO). The IPO will consist of fresh equity shares worth Rs 300 crore and an Offer For Sale of 89.39 lakh equity shares by the company's promoter. The company may also consider a pre-IPO placement of up to Rs 60 crore. Proceeds from the IPO will be used to pay debt, support working capital needs, fund capital expenditure, and expand product offerings.
Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) major shareholder Global Investors Lp Viking sold 13,000,000 shares of the stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $9.90, for a total value of $128,700,000.00. Following the transaction, the insider now directly owns 641,010 shares of […]
Cantor Fitzgerald restated their overweight rating on shares of Roivant Sciences (NASDAQ:ROIV – Get Rating) in a research report sent to investors on Tuesday morning, PriceTargets.com reports. A number of other equities analysts also recently weighed in on ROIV. JPMorgan Chase & Co. boosted their price target on shares of Roivant Sciences from $12.00 to […]
Roivant Sciences (NASDAQ:ROIV – Get Rating) and 23andMe (NASDAQ:ME – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership. Institutional and Insider Ownership 60.6% of Roivant Sciences shares are owned […]